Skip to main content
MAYNE PHARMA GROUP LIMITED logo

MAYNE PHARMA GROUP LIMITED — Investor Relations & Filings

Ticker · MYX ISIN · AU000000MYX0 LEI · 549300VIRDEN0N4MJG59 ASX Manufacturing
Open in API
Filings indexed 1,116 across all filing types
Latest filing 2026-05-21 Legal Proceedings Report
Country AU Australia
Listing ASX MYX

About MAYNE PHARMA GROUP LIMITED

https://www.maynepharma.com

Mayne Pharma Group Limited is a specialty pharmaceutical company focused on the development and commercialization of branded and generic medicines. The company operates through specialized segments including Women's Health and Dermatology. Its Women's Health portfolio features innovative contraceptive solutions, while the Dermatology division provides a broad range of treatments for various skin conditions. Beyond its product portfolio, the company provides contract development and manufacturing services (CDMO), leveraging proprietary drug delivery technologies to produce complex oral and topical dosage forms. The organization focuses on high-growth specialty markets, aiming to deliver differentiated therapeutic options and improve patient outcomes through technical excellence and strategic commercialization.

Recent filings

Filing Released Lang Actions
Court awards MYX $13.27m for legal costs from Cosette 2 pages 162.3KB
Legal Proceedings Report Classification · 92% confidence The document is a public ASX announcement detailing the outcome of legal proceedings in which Mayne Pharma was awarded legal costs by the Supreme Court. It provides an update on a significant lawsuit and court judgment, with no financial report data or meeting details. This fits squarely into the Legal Proceedings Report category.
2026-05-21 English
Mayne Pharma announces expansion of Adelaide Apothecary 3 pages 217.4KB
Regulatory Filings Classification · 87% confidence The document is an ASX announcement providing general business news about a new leased facility and associated capital expenditure for Mayne Pharma’s specialty pharmacy subsidiary. It does not represent a financial report, fundraising/financing terms, dividends, or an operational earnings release. It is not raising equity or debt but simply discloses strategic asset expansion and capex projections. As such it falls into the fallback “Regulatory Filings” category for miscellaneous ASX regulatory disclosures that do not fit other specific categories.
2026-05-17 English
Mayne Pharma 3Q investor presentation 24 pages 1.2MB
Investor Presentation Classification · 100% confidence The document is titled 'MAYNE PHARMA 3Q INVESTOR PRESENTATION' and dated 7 May 2026. It provides a detailed overview of the company's third quarter financial results for fiscal year 2026, including revenue, EBITDA, segment performance, and strategic initiatives. The content includes financial metrics, operational highlights, segment analysis, and forward-looking statements typical of an investor presentation. The document is about 15,000 characters long, indicating it is a full presentation rather than a brief announcement. It explicitly states it is an 'Investor Presentation' and includes detailed financial and strategic information aimed at investors. Therefore, the document fits the category of an Investor Presentation (IP).
2026-05-06 English
Notification of cessation of securities - MYX 4 pages 14.9KB
Regulatory Filings Classification · 95% confidence The document is titled 'Appendix 3H - Notification of cessation of securities' and details the lapse of performance rights (unquoted equity securities) for Mayne Pharma Group Limited. It provides specific information about the securities that have ceased, the reason for cessation, and the updated issued capital following these changes. This type of announcement is a regulatory filing notifying the market and ASX about changes in the company's securities, specifically cessation of securities. It is not a financial report, earnings release, or management discussion. The document length is 3498 characters, which is relatively short and focused on a specific securities cessation event. Therefore, it fits best under Regulatory Filings (RNS) as a general regulatory announcement about securities changes that does not fit other more specific categories like Share Issue/Capital Change (SHA) or Director's Dealing (DIRS).
2026-05-03 English
Further details re equity instruments to be issued to CEO 3 pages 191.6KB
Remuneration Information Classification · 95% confidence The document is an ASX announcement providing detailed information about equity instruments to be issued to the CEO, including terms of sign-on bonuses, long-term incentive awards, vesting criteria, and other related conditions. It is not a full financial report, earnings release, or management discussion. It is a specific announcement about remuneration-related equity awards to a senior executive. This fits best under the category of Remuneration Information (DEF 14A), which covers reports detailing compensation for top executives and directors. The document is 8332 characters long, contains detailed terms of equity awards, and is not merely an announcement of a report or a regulatory filing. Therefore, the classification is DEF 14A with high confidence.
2026-04-29 English
Mayne Pharma reports unaudited 3Q FY26 results 5 pages 297.6KB
Interim / Quarterly Report Classification · 95% confidence The document is an ASX announcement titled 'MAYNE PHARMA REPORTS UNAUDITED 3Q FY26 RESULTS' and provides detailed financial and operational updates for the three months ended 31 March 2026 (3Q FY26). It includes revenue, gross profit, EBITDA, cash flow figures, segment performance, and outlook commentary. The document is approximately 13,623 characters long, which is substantial and contains actual financial data and analysis for a quarterly period. The content is consistent with a comprehensive interim or quarterly financial report rather than a brief earnings release or a simple announcement of report publication. There is no indication that this is a full annual report (10-K) or an audit report. The focus on quarterly results and detailed financial metrics aligns with the definition of an Interim / Quarterly Report (IR).
2026-04-28 English

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.